Back to search results
Completed

Mild Cognitive Impairment, Mild Alzheimer's, Early Symptoms of Alzheimer's Disease, Moderate Alzheimer's

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

LAKA | {{ defaultRegistry.registryAnchorText }} NCT03720548 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

Completed Study

The results of this study are not yet available.

Time Commitment

Part A will last up to 17 weeks and may include up to 14 visits. Part B will last up to 317 days and may include 16 visits.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18 years
85 years
  • (Part A): Participants must be men or women in good health, between the ages of 18-45 (inclusive).
  • (Part A): Participants must not have memory or thinking problems or a family history of early onset AD.
  • (Part A): Male participants must agree to use birth control throughout the study and for 3 months after the last dose of the study drug. Female participants must not be able to bear children.
  • (Part B): Participants must be men or women, ages 55-85 (inclusive), with mild cognitive impairment or mild-moderate dementia due to Alzheimer’s disease.
  • (Part B): Participants must have a positive florbetapir scan and must be able to participate in MRI scans.
  • (Part B): Male participants must agree to use birth control throughout the study and for 3 months after the last dose of the study drug. Female participants must not be able to bear children.
  • (Part B): Participants must not be allergic to a common type of allergy medicine (antihistamines), epinephrine, or corticosteroids.”
  • (Part B): Participants must not have any significant medical or neurological illnesses that could affect the study results.
  • (Part B): Participants must have a study partner who can provide health information related to the study about the participant throughout the study.

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.